A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients ( ≥ 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
This randomized phase III trial studies rituximab with bendamustine hydrochloride or
ibrutinib to see how well they work compared to ibrutinib alone in treating older patients
with previously untreated chronic lymphocytic leukemia. Monoclonal antibodies, such as
rituximab, can block cancer growth in difference ways. Some block the ability of cancer
cells to grow and spread. Others find cancer cells and help kill them or carry
cancer-killing substances to them. Drugs used in chemotherapy, such as bendamustine
hydrochloride, work in different ways to stop the growth of cancer cells, either by killing
the cells or by stopping them from dividing. Ibrutinib may stop the growth of cancer cells
by blocking some of the enzymes needed for cell growth. It is not yet know whether rituximab
with bendamustine hydrochloride is more effective than rituximab and ibrutinib or ibrutinib
alone in treating chronic lymphocytic leukemia.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.